Bevacizumab In Hereditary Hemorrhagic Telangiectasia
NCT04404881
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
DRUG:
Bevacizumab (Avastin®)
Sponsor
Hanny Al-Samkari, MD